Radioligand Therapy 177Lu-PSMA-617 in Patients With Progressive PSMA-positive mCRPC

Evan Y. Yu, MD, shares insight on the rationale for precision medicine in patients with progressive PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have been previously treated with androgen axis inhibitor drugs and taxane.

Dr Evan Y. Yu reviews the use of 177Lu-PSMA-617 therapy in patients with progressive PSMA-positive mCRPC as seen in the phase 3 VISION trial.

An expert in prostate cancer comments on patient response to 177Lu-PSMA-617 therapy, particularly for patients with mCRPC who have liver metastases.

Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.

Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.